Navigation Links
Drug Treatment Market For Obesity Will Increase More Than Five-Fold, Reaching $2.7 Billion in 2016
Date:3/25/2008

Growth Will Be Driven by Novel Emerging Therapies, Including Drugs from

Arena and Amylin, According to a New Report from Decision Resources

WALTHAM, Mass., March 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the obesity drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will experience more than five-fold growth, rising from $478 million in 2006 to more than $2.7 billion in 2016. The market will grow most rapidly in the United States, where sales will increase from $222 million in 2006 to nearly $2 billion in 2016.

The new Pharmacor report entitled Obesity finds that the significant market growth will be driven by a number of emerging therapies, including Arena Pharmaceuticals' lorcaserin and Amylin Pharmaceuticals' pramlintide/leptin combination, which are both expected to launch in the world's major pharmaceutical markets by 2011. Lorcaserin, pramlintide/leptin and other emerging novel therapies will capture 80% of the total obesity market in 2016 as physicians switch from the few currently available therapies to new treatments with novel mechanisms of action.

The report also finds that increasing concern of the Food and Drug Administration (FDA) regarding the long-term safety of drug treatments for chronic conditions such as obesity poses one of the most significant threats to companies developing anti-obesity drugs. For example, although Sanofi- Aventis's Acomplia (rimonabant) had been widely anticipated to become a key therapy for obesity, its blockbuster potential was eliminated after a negative opinion of the drug was issued by an FDA advisory panel last year. According to the report, similar safety concerns will plague Merck's taranabant and Pfizer's CP-945598, which belong to the same drug class as rimonabant.

"Given the high prevalence of obesity in the world's major pharmaceutical markets, the opportunity for agents that fulfill the need for safe, effective and well-tolerated weight-loss therapies is significant," said Donny Wong, Ph.D. principal analyst at Decision Resources. "Although the most efficacious emerging obesity drugs are combination therapies with multiple mechanisms of action, most of the late-stage therapies in development lack blockbuster potential because they are either associated with safety concerns or are available only in inconvenient injectable formulations."

About Obesity

The obesity epidemic is recognized as one of the most important public health challenges in the world. In 2006, the prevalent population of obese and overweight individuals in the world's major pharmaceutical markets surpassed 300 million. The U.S. Centers for Disease Control and Prevention predicts that obesity-related illnesses will soon overtake smoking-related illnesses as the leading cause of mortality in the United States. The rising cost of treating obesity-related illnesses such as type 2 diabetes and cardiovascular disease poses huge challenges to national healthcare systems worldwide.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cancer treatments in phase 3 trials successful up to half of the time
2. FSU researchers mutant proteins could lead to new treatment for heart disease
3. WellPoints Health Plans to Cover Newly Approved Cancer Treatment
4. TB Drug Treatment Can Lead to Severe Pneumonia
5. Youth sports concussion program points to need for proper treatment of concussion in children
6. Prostate size and other neglected factors influence prostate cancer treatment satisfaction
7. Quality of Life an Issue in Prostate Cancer Treatment
8. Molecular biology of sleep apnea could lead to new treatments
9. One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines
10. Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments
11. Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
Breaking Medicine Technology: